Dr. A. Deevan Paul is a young researcher and leading nanotechnologist currently working as an Assistant Professor at the Department of Pharmaceutics, Sri Ramachandra Faculty of Pharmaceutical Sciences, SRIHER, Chennai. He completed his Ph.D. at JNU in 2019 entitled “Formulation and Evaluation of Orodispersible Dosage Forms Incorporating Drug-loaded Nanoparticles”. He published more than 42 research papers in high-impact international journals and gave his talks at various reputed colleges and universities all around India. He received the “Best Research Award” organized by APTI at JNTU Hyderabad 2022. He earned 4 patents, of which two got published and 2 got granted in Intellectual Property Rights, India for his excellence in research in drug-loaded nanotechnology. He is a life member of the Indian Science Congress, govt of India. He has 12 years of academic and research experience.
Cardiac arrest and hyperlipidemia represent significant and recurrent global health challenges. Lipid nanoparticles are widely recognized for their exceptional stability and capacity for high drug loading. Addressing the low bioavailability and limited therapeutic efficacy associated with hyperlipidemia-related cardiovascular diseases, this study focuses on loading Atorvastatin (AT) and Clopidogrel (CL) into lipid nanoparticles. We have developed three different technologies among which Solid lipid nanoparticles incorporating AT-CL were developed, with the S3 formulation demonstrating an Entrapment Efficiency (EE) of 76.9 ± 1.8% and an in-vitro drug release of 76.15 ± 3.5% after 24 hours, indicating the initiation of drug extrusion due to available free space within the solid lipids. Conversely, liquid lipid nanoparticles loaded with the drugs exhibited enhanced performance, particularly formulation L3, showcasing an EE of 84.6 ± 2.3% and an in-vitro drug release of 84.67 ± 4.3% after 24 hours. However, the inclusion of liquid components compromised stability.
We have achieved a Box-Behnken design involving 13 different runs for Nanostructured lipid carriers (NLC) using ‘3’ factors and ‘4’ responses. The particle size was found to be 164.5 ± 1.5nm, a polydispersity index (PDI) of 0.2252 ± 0.051, a zeta potential of -23.65 ± 1.4mV, an EE of 93.5 ± 3.4%, and an in-vitro drug release of 92.18 ± 2.2% in 24 hours.
Current anticoagulant therapies often lack efficacy, particularly in high-risk patients with conditions like atrial fibrillation, deep vein thrombosis, or pulmonary embolism. We propose a novel technology involving dabigatran-loaded silver nanoparticles, exhibiting synergistic activity for enhanced anticoagulant potential. This technology offers improved solubility, targeted delivery, reduced side effects, combined anticoagulants, and platelet inhibitors. Our systematic approach involves refining through chemical reduction methods and exploring using green synthesis in formulation. Physicochemical characterization guides the optimization process, aided by Design Expert software. Incorporating suitable biodegradable polymers through green synthesis methods enhances the potential for optimized anticoagulant therapy, efficacy, and safety, thereby revolutionizing the management of thrombotic conditions. The prepared formulations were characterized for particle size distribution, Polydispersity Index, Encapsulation Efficiency (EE%), Zeta potential, surface morphology, and physical state characteristics. In vitro, drug release profile analysis utilizing the dialysis bag method validated the release profile using various mathematical models. The prepared silver nanoparticles exhibit a particle size of 315±5.75nm, a Polydispersity index (PDI) of 0.686±0.001, and a zeta potential of -33.50±0.001 mV. The encapsulation efficiency was measured at 92.42±2.31%.
RECIEVED BEST RESEARCH AWARD IN “INTERNATIONAL CONFERENCE ON CURRENT ADVANCES IN PHARMACEUTICAL INDUSTRY AND DEVELOPMENT” CONDUCTED BY JNTUH, HYDERABAD.
INDIAN SCIENCE CONGRESS (ISC) – LIFE MEMBER